Zimmer Biomet Holdings (ZBH) Cash & Equivalents (2009 - 2026)

Zimmer Biomet Holdings has reported Cash & Equivalents for 18 years, with the latest figure at $410.0 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 26.38% year-over-year to $410.0 million in Q2 2026; TTM through Jun 2026 was $410.0 million, a 26.38% decrease from a year earlier, with the FY2025 full-year figure at $591.9 million, up 12.64% from the prior year.
• Cash & Equivalents was $410.0 million for Q2 2026 at Zimmer Biomet Holdings, down from $424.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.4 billion in Q1 2025, with the low at $292.1 million in Q3 2023.
• Average Cash & Equivalents over 5 years is $537.2 million, with a median of $422.2 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents jumped 252.29% in 2025, then plunged 69.36% in 2026.
• Over 5 years, Cash & Equivalents stood at $375.7 million in 2022, then grew by 10.67% to $415.8 million in 2023, then gained by 26.38% to $525.5 million in 2024, then grew by 12.64% to $591.9 million in 2025, then plunged by 30.73% to $410.0 million in 2026.
• The last three Cash & Equivalents figures came in at $410.0 million (Q2 2026), $424.2 million (Q1 2026), and $591.9 million (Q4 2025), per Business Quant data.